Abstract
Purpose of Review To provide a highlight of the current state of cell therapy for the treatment of critical limb ischemia in patients
with diabetes.
Recent Findings The global incidence of diabetes is constantly growing with consequent challenges for healthcare systems
worldwide. In the UK only, NHS costs attributed to diabetic complications, such as peripheral vascular disease, amputation,
blindness, renal failure, and stroke, average £10 billion each year, with cost pressure being estimated to get worse. Although giant
leaps forward have been registered in the scope of early diagnosis and optimal glycaemic control, an effective treatment for
critical limb ischemia is still lacking. The present review aims to provide an update of the ongoing work in the field of
regenerative medicine. Recent advancements but also limitations imposed by diabetes on the potential of the approach are
addressed. In particular, the review focuses on the perturbation of non-coding RNA networks in progenitor cells and the
possibility of using emerging knowledge on molecular mechanisms to design refined protocols for personalized therapy.
Summary The field of cell therapy showed rapid progress but has limitations. Significant advances are foreseen in the upcoming
years thanks to a better understanding of molecular bottlenecks associated with the metabolic disorders.
with diabetes.
Recent Findings The global incidence of diabetes is constantly growing with consequent challenges for healthcare systems
worldwide. In the UK only, NHS costs attributed to diabetic complications, such as peripheral vascular disease, amputation,
blindness, renal failure, and stroke, average £10 billion each year, with cost pressure being estimated to get worse. Although giant
leaps forward have been registered in the scope of early diagnosis and optimal glycaemic control, an effective treatment for
critical limb ischemia is still lacking. The present review aims to provide an update of the ongoing work in the field of
regenerative medicine. Recent advancements but also limitations imposed by diabetes on the potential of the approach are
addressed. In particular, the review focuses on the perturbation of non-coding RNA networks in progenitor cells and the
possibility of using emerging knowledge on molecular mechanisms to design refined protocols for personalized therapy.
Summary The field of cell therapy showed rapid progress but has limitations. Significant advances are foreseen in the upcoming
years thanks to a better understanding of molecular bottlenecks associated with the metabolic disorders.
| Original language | English |
|---|---|
| Article number | 11 |
| Journal | Current Diabetes Reports |
| Volume | 21 |
| DOIs | |
| Publication status | Published - 2 Mar 2021 |
Access to Document
- Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Springer at https://doi.org/10.1007/s11892-021-01378-4 . Please refer to any applicable terms of use of the publisher.